Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH
Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH
Enrolling by invitation · NCT07102511 · Registry updated 2026-07-28Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH | Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, hyperlipidemia, metabolic disease | Enrolling by invitation | Phase 3 | 2026-07-28 | NCT07102511 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| LIB Therapeutics LLC | 3 |
| Medpace, Inc. | 17 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ege Universitesi Tip Fakultesi | Izmir | Turkey (Türkiye) | 4 |
| Iatros International | Bloemfontein | South Africa | 1 |
| Lipid Clinic Hadassah Medical Center | Jerusalem | Israel | 1 |
| Lipid Clinic Wits University | Johannesburg | South Africa | 1 |
| Metabolic & Atherosclerosis Research Center | Cincinnati | United States | 1 |
| New Zealand Clinical Research | Christchurch | New Zealand | 4 |
| The Lipid Clinic Oslo University Hospital | Oslo | Norway | 1 |